isoniazid has been researched along with orphenadrine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashizume, H; Kawasaki, M; Komatsu, M; Matsumoto, M; Sasaki, H; Shimokawa, Y; Tomishige, T; Tsubouchi, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Lee, JH; Lee, MG; Yang, KH | 1 |
| Choi, YH; Lee, JH; Lee, MG; Lee, U; Yang, KH | 1 |
1 review(s) available for isoniazid and orphenadrine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for isoniazid and orphenadrine
| Article | Year |
|---|---|
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
Topics: Animals; Antitubercular Agents; Blood; Cell Line; Humans; In Vitro Techniques; Intracellular Membranes; Macrophages; Mammals; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium; Mycobacterium bovis; Mycolic Acids; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Effects of CYP inducers and inhibitors on the pharmacokinetics of intravenous theophylline in rats: involvement of CYP1A1/2 in the formation of 1,3-DMU.
Topics: Animals; Area Under Curve; Benz(a)Anthracenes; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Dexamethasone; Dose-Response Relationship, Drug; Enzyme Activators; Half-Life; Infusions, Intravenous; Isoniazid; Metabolic Clearance Rate; Methylcholanthrene; Orphenadrine; Phosphodiesterase Inhibitors; Protein Binding; Rats; Rats, Sprague-Dawley; Theophylline; Uric Acid; Weight Gain | 2008 |
Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism.
Topics: Animals; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cimetidine; Cytochrome P-450 Enzyme System; Diuretics; Drug Interactions; Enzyme Activators; Enzyme Inhibitors; Furosemide; Half-Life; Infusions, Intravenous; Injections, Intravenous; Isoniazid; Male; Methylcholanthrene; Orphenadrine; Proadifen; Quinine; Rats; Rats, Sprague-Dawley; Troleandomycin; Weight Gain | 2009 |